VIVES is a multi-sector fund that invests in projects with a positive societal impact
Viridaxis is a specialist in development and supply of efficient and effective natural aphid control methods for the agricultural sector. Their R&D activities include applied field research to...
iTeos Therapeutics targets the tumor microenvironment to boost immune cell efficiency in cancer eradication.
Immunotherapy is a revolutionary approach to cancer treatment that aims to educate the...
The Tessares solution combines existing fixed and mobile networks to increase DSL speed with the speed of the 4G mobile network. This is called "Hybrid Internet", which immediately speeds up the speed...
Pierre Drion, business angel:
"For almost 20 years I have been passionate about what is called BioTech. This led me to invest in several companies and mainly university spin-offs. In this context, I...
Vincent Mouret, Chairman of the Board of Cissoid:
"As Chairman of the board of Cissoid, I’ve been working closely to VIVES for the last 10 years. I have really appreciated VIVES involvement and...
Pierre-Antoine Mariage, co-CEO Botalys:
"VIVES trusted us at an early stage. In addition to their financial investment, they offer us a regular and wise coaching from their experts while respecting...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is